Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
MORGANTOWN, W. Va., Feb. 02, 2016 -- Protea Biosciences Group, Inc., (OTCQB:PRGB) announced that the Company will be presenting at the BIO CEO & Investor Conference taking place on February 8-9, 2016 at the Waldorf Astoria Hotel in New York City. Stephen Turner, Chairman and CEO, will present at 8:30 am ET on Monday, February 8, 2016.
To listen to the live audio webcast of the presentation during the event, please visit:
http://www.veracast.com/webcasts/bio/ceoinvestor2016/34103292263.cfm
A replay of the webcast will be available for 90 days after the initial presentation.
Management will be available for one-on-one meetings with conference attendees. Meetings can be arranged through the conference's partnering system at http://www.bio.org/events/conferences/bio-ceo-investor-conference or by contacting the Company at [email protected].
About Protea Biosciences
Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing innovative bio-analytical technology to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's proprietary technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the byproducts of all living cells and life forms.
For more Information:
Protea Biosciences Group, Inc., 1311 Pineview Dr., Morgantown, WV 26505 USA
Phone: 304.292.2226 Fax: 304.606.3049
https://proteabio.com/investors
Protea is a registered trademark of Protea Biosciences Group, Inc.
